Evidence for enhancer noncoding RNAs (enhancer-ncRNAs) with gene regulatory functions relevant to neurodevelopmental disorders

Yazdan Asgari¹,², Julian I.T. Heng³,⁴, Nigel Lovell⁵, Alistair R. R. Forrest⁶, Hamid Alinejad-Rokny*²,⁷,⁸

¹Health Data Analytics Program Leader, AI-enabled Processes (AIP) Research Centre, Macquarie University, Sydney, 2109, AU.
²Department of Medical Biotechnology, School of Advanced Technologies in Medicine, Tehran University of Medical Sciences, Tehran, IR. (yasgari@tums.ac.ir)
³Curtin Health Innovation Research Institute, Curtin University, Bentley 6845, AU. (julian.heng@curtin.edu.au)
⁴School of Pharmacy and Biomedical Sciences, Curtin University, Bentley 6845, AU.
⁵The Graduate School of Biomedical Engineering, UNSW Sydney, Sydney, NSW, 2052, AU. (n.lovell@unsw.edu.au)
⁶Harry Perkins Institute of Medical Research, QEII Medical Centre and Centre for Medical Research, the University of Western Australia, Nedlands, Perth, WA, 6009, AU. (alistair.forrest@perkins.uwa.edu.au)
⁷Systems Biology and Health Data Analytics Lab, the Graduate School of Biomedical Engineering, UNSW Sydney, Sydney, NSW, 2052, AU.
⁸School of Computer Science and Engineering, UNSW Sydney, Sydney, NSW, 2052, AU.

* Correspondence should be addressed to H.A.R. Tel: +61 2 9385 3911; e-mail: h.alinejad@unsw.edu.au.

Abstract

Noncoding RNAs (ncRNAs) comprise a significant proportion of the mammalian genome, but their biological significance in neurodevelopment disorders is poorly understood. In this study, we identified 908 brain-enriched noncoding RNAs comprising at least one nervous system-related eQTL polymorphism that is associated with protein coding genes and also overlap with chromatin states characterised as enhancers. We referred to such noncoding RNAs with putative enhancer activity as brain ‘enhancer-ncRNAs’. By integrating GWAS SNPs and Copy Number Variation (CNV) data from neurodevelopment disorders, we found that 265 enhancer-ncRNAs were either mutated (CNV deletion or duplication) or contain at least one GWAS SNPs in the context of such conditions. Of these, the eQTL-associated gene for 82 enhancer-
ncRNAs did not overlap with either GWAS SNPs or CNVs suggesting in such contexts that mutations to neurodevelopment gene enhancers disrupt ncRNA interaction. Taken together, we identified 49 novel NDD-associated ncRNAs that influence genomic enhancers during neurodevelopment, suggesting enhancer mutations may be relevant to the functions for such ncRNAs in neurodevelopmental disorders.

Keywords: Neurodevelopmental disorders, Autism spectrum disorders, Schizophrenia, Noncoding RNAs, Enhancer, Gene regulation, Noncoding RNAs prioritisation.

Introduction

Neurodevelopmental disorders (NDDs) represent a group of early onset disorders that arise as a result of defective nervous system development during prenatal and early postnatal stages. In NDDs which are associated with abnormal brain development, individuals may present with severe difficulties in emotional regulation, speech and language, autistic behavior, abnormalities of the endocrine system, attention deficit hyperactivity disorder, cognitive impairment, psychosis, and schizophrenia [1]. It is known that genetic, epigenetic, and environmental insults can disrupt the development of the central nervous system, including the birth of neural cells, their positioning and connectivity as functional units within brain circuitry, as well as their capacity for signal propagation [2]–[4]. As a corollary, NDDs arise as a consequence of defective neurogenesis, aberrant cell migration essential to neuronal positioning during circuit formation, as well as from dysfunctional synaptogenesis and aberrant synaptic pruning [5]. Despite significant advances in clinical insights into NDDs, the molecular mechanisms which underlie these often lifelong neurological conditions remains poorly characterised [1].

Our understanding of the genomic regulation of mammalian development, homeostasis and disease has been facilitated by significant technological advances in sequencing. As an example, since the discovery of noncoding RNAs (ncRNAs) [6], their diversity of subtypes, and their myriad roles in homeostasis and disease are becoming better understood. At present, ncRNAs can be classified into multiple
groups, including transfer RNAs (tRNAs), ribosomal RNAs (rRNAs), microRNAs (miRNAs), Piwi-interacting RNAs (piRNAs), small interfering RNAs (siRNAs), small nucleolar RNAs (snoRNAs), small nuclear RNAs (snRNAs), extracellular RNAs (exRNAs), small cajal body-specific RNAs (scaRNAs), and long ncRNAs (lncRNAs) [7]. Of note, recent evidence is indicative of significant roles for ncRNAs in brain function and behavior. As a corollary, ncRNAs are implicated in the etiology of conditions including bipolar disorder, schizophrenia, autism, and language impairment [8][9]. Anecdotally, the functions for several ncRNAs species including H19, KCNQ1OT1, SNORD115, and SNORD116, all of which have been demonstrated to be relevant to neurodevelopment, are associated with NDDs [10][11]. Moreover, several large-scale studies have been characterised ncRNA functions in human neuropathological phenotypes [12][13][14], [15], yet the regulatory actions for ncRNAs in NDDs remains unclear.

In this study, we have investigated a curated set of noncoding RNAs for gene regulatory functions in neurodevelopment and NDDs, using an integrative bioinformatics pipeline. By integrating genomic and epigenetic datasets on these ncRNA species, analysing their ENCODE regulatory features, FANTOM5 tissue-specific enhancer traits, FANTOM5 expression profiles, nervous system-related expression quantitative trait loci (eQTLs) mapping, neurodevelopment-related GWAS single nucleotide polymorphisms (SNPs), and Copy Number Variation (CNV); we have identified a set of noncoding RNAs with evidence of gene regulatory functions in neurodevelopment and disease.

**Results**

An overview of the pipeline used in this study is provided as Figure 1. As shown, we utilised the resource FANTOMCAT [16] to identify noncoding RNAs that are significantly enriched in brain tissue. Next, we annotated brain-enriched ncRNAs with ENCODE predicted chromatin states/histone modifications to identify promoters and enhancers for brain-enriched ncRNAs. These ncRNAs within enhancer loci are then investigated for their association with eQTLs to identify their linkage to a coding gene. Based on these criteria, we refer to these as neuronal ‘enhancer-ncRNAs’. Using data on CNVs and GWAS SNPs related to neurodevelopmental conditions, we then cross-
referenced these datasets to identify enhancer ncRNAs that are mutated in individuals with NDDs, then focus on those enhancer ncRNAs in which an NDD mutation or CNV disrupts their association with a coding gene. Therefore, through these selection criteria, we identify a set of ncRNAs with putative gene regulatory roles relevant to NDDs.

**Noncoding RNAs with histone mark and ChromHMM signals**

We curated a set of noncoding RNAs comprising 60,681 noncoding genes including 31,343 long noncoding RNAs, from FANTOMCAT (Figure 2a). Brain-related ncRNAs were identified based on their mapping to ChromHMM-predicted promoter or enhancer loci. To do this, we selected genes corresponding to brain–specific promoter or enhancer regions (see Methods for details). Of 22,698 coding genes, 6,636 (29.24%) overlapped with promoters, 1,095 (4.82%) overlapped with enhancers, and 7,731 (34.06%) overlapped with either promoters or enhancers (Figure 2b and Supplementary table S1). Furthermore, of 60,681 noncoding genes, 5,736 of them (9.45%) overlapped with promoters, 2,945 (4.85%) overlapped with enhancers and 8,681 (14.31%) overlapped with either promoters or enhancers (Figure 2c and Supplementary table S1). In subsequent analyses, we only analyse noncoding genes that overlapped with either promoters or enhancers.

**eQTL polymorphism suggests enhancer activity for ncRNAs**

eQTLs are genomic loci that affect expression levels of genes in one or multiple tissues [17], [18], [19]. To identify noncoding RNAs that contain at least one brain-related eQTL polymorphism, we utilised data on eQTL pairs relevant to the nervous system from the Genotype-Tissue Expression (GTEx) Project [19].

When we performed this analysis with 60,681 noncoding genes, we found 17,743 (29.24%) that contained at least one eQTL polymorphism related to nervous system tissues, including 3,196 in Amygdala, 5,621 in Anterior Cingulate Cortex, 7,612 in Caudate Basal Ganglia, 8,682 in Cerebellar Hemisphere, 10,900 eQTL pairs in Cerebellum, 8,242 eQTL pairs in Cerebral Cortex, 6,476 eQTL pairs in Frontal Cortex, 4,462 eQTL pairs in Hippocampus, 4,503 eQTL pairs in Hypothalamus, 6,818 eQTL pairs in Nucleus Accumbens Basal Ganglia, 5,547 eQTL pairs in Putamen Basal...
Ganglia, 3,553 eQTL pairs in Spinal Cord Cervical, and 2,586 eQTL pairs in Substantia Nigra (Supplementary table S2).

We performed hierarchical clustering of 17,743 noncoding RNA genes that contained at least one nervous system related eQTL polymorphism based on their expression profiles. Through this approach, we found that a substantial proportion of genes are highly expressed in brain tissue, with smaller clusters of genes that are highly expressed in blood and T-cells, as well as granulocytes (Figure 3). This clustering also reveals a smaller, but nonetheless significant clustering of ncRNA genes highly expressed in testis, and within the male reproductive system (Figure 3, in green). Next, we investigated the distribution of eQTL polymorphisms across noncoding genes based on their ncRNA sub-classification. As shown in Table 1, across 13 different eQTL brain sub-regions, the majority of nervous system related eQTL polymorphisms are relevant to 17,743 IncRNAs (64.81%), followed by pseudogenes 21.93%, miRNAs 0.31%, antisense ncRNAs 4.68%, sense overlapping ncRNAs 2.09%, misc_RNAs 0.58%, snRNAs 0.25%, snoRNAs 0.24%, rRNAs 0.11%, 3prime overlapping ncRNAs 0.03%, but not tRNAs (0%). In addition, ncRNAs which do not sub-classify to these categories constitute a small proportion (4.96%). Thus, brain eQTL associated genes, on average, interact with 5.87 coding- and 3.18 noncoding genes that contain at least one brain related eQTL polymorphism (Supplementary table S3). This suggests that interactions between coding genes are preferred in nervous tissue.

Of the 17,743 noncoding RNAs characterised with at least one nervous system-related eQTL polymorphism (Supplementary table S2), we find interactions with 0.47 coding genes per ncRNA (8,399 coding genes, with interactions defined as more than 0.002kb and less than 2,213kb from ncRNA, and with the average distance of 170kb - Supplementary table S4). These ncRNAs are interacting with an average of 0.08 noncoding genes (1,466 non-coding gene interactions identified).

Out of 17,743 noncoding RNAs (encompassing at least one nervous system related eQTL polymorphism), 14,530 ncRNAs interact with at least one protein-coding gene through eQTL pair including 1,866 in Amygdala, 3,718 in Anterior Cingulate Cortex, 5,258 in Caudate Basal Ganglia, 6,383 in Cerebellar Hemisphere, 8,675 eQTL pairs in Cerebellum, 5,869 eQTL pairs in Cerebral Cortex, 4,313 eQTL pairs in Frontal Cortex, 2,741 eQTL pairs in Hippocampus, 4,571 eQTL pairs in Hypothalamus, 4,571
eQTL pairs in Nucleus Accumbens Basal Ganglia, 3,711 eQTL pairs in Putamen Basal Ganglia, 2,229 eQTL pairs in Spinal Cord Cervical, and 1,410 eQTL pairs in Substantia Nigra (Supplementary table S5). The distribution of brain eQTL polymorphisms on different types of noncoding genes is illustrated in Supplementary table S6.

**Identify brain-enriched noncoding genes**

We next used the FANTOM CAGE (Cap Analysis of Gene Expression) associated transcript database [16] and the FANTOM5 expression atlas [20] to characterise tissue-specificity features for noncoding genes. Of the 17,743 noncoding RNAs analysed, 7,164 are significantly expressed in nervous systems tissue (see Methods). Notably, the overwhelming majority (99.9%, 7163 out of 7164) are lncRNAs, with the exception of ENSG00000214857, which is a pseudogene (Supplementary table S7).

Next, we characterised brain-related noncoding RNAs with enhancer activity, based on the following criteria: these noncoding RNAs (i) are significantly enriched in brain tissue expression; (ii) are overlapping ENCODE-predicted chromatin states which identify enhancer and promoter loci; and (iii) are mapping to eQTL polymorphisms that interact with at least one protein-coding gene. Based on these criteria, we found 908 of 60,681 noncoding RNAs annotated as putative enhancers in brain tissue, which include 907 lncRNA and 1 pseudogene (Supplementary table S8). We refer to these as putative enhancer ncRNAs (enhancer-ncRNAs).

**Annotating ncRNAs with genome-wide association study SNPs**

Next, we investigated these 908 putative “enhancer-ncRNAs” for potential regulatory function in neurodevelopmental disorders. To achieve this, we asked if enhancer-ncRNAs were associated with GWAS SNPs or CNV deletion or duplication loci documented in NDD patients. As a corollary, it has been reported that more than 96% of disease associated variants detected in genome-wide association studies (GWAS) map to the noncoding regulatory regions of genomes [21], suggesting a role in human disease. We found that of 908 enhancer-ncRNAs, 89 of these (9.8%) contain at least one GWAS SNP related to a neurodevelopmental disorder (Supplementary table S9). This is higher (P-value: 8.0e-02), when compared against 1,496 (8.4%)
noncoding genes with at least one nervous system related eQTL polymorphism in our dataset (Supplementary table S10), and is also significantly higher (P-value: 1.9e-14) when compared to the 2,390 (4.8%) of all 60,681 noncoding genes which contain at least one GWAS SNP. Table 2 shows the proportion of GWAS SNPs across neurodevelopmental disorders relevant to these 89 enhancer noncoding genes. Of these, we found that 68 IncRNAs are relevant to Schizophrenia-related GWAS SNPs, while 10 IncRNAs are associated with Psychosis, 9 IncRNAs with Attention Deficit Hyperactivity Disorder (ADHD), 9 IncRNAs Cognitive Impairment, 7 IncRNAs with Abnormality of the Nervous System, 2 IncRNAs Autistic Behavior, 2 IncRNAs Abnormality of emotion, 1 IncRNA Abnormality of metabolism, 1 IncRNA Abnormality of the endocrine system, and 1 IncRNA Language impairment. Notably, we find 20 IncRNAs which are associated with GWAS SNPs categorised to two or more neurodevelopmental disorders (Table 2 and Supplementary table S9).

Interestingly, we also found that for 56 enhancer-ncRNAs (out of 68 noncoding genes related to schizophrenia) there is no GWAS SNP in their eQTL linked coding gene. For non-schizophrenia NDDs (which we term “other NDDs”), we find 24 enhancer-ncRNAs in which there was no GWAS SNP detected in their eQTL linked coding gene (Table 3). Equally noteworthy is our finding that 14 ncRNAs for schizophrenia represent important associative loci, since they map to GWAS SNP loci relevant to neurodevelopmental disorder, while their eQTL genes do not contain a GWAS SNP signature, nor does their eQTL genes have interactions with any other eQTL data with a GWAS SNP (Table 3). These criteria also identify 8 ncRNAs as novel factors for NDDs which do not include schizophrenia (Table 3). These data suggest that noncoding RNA may be relevant to modulating expression in these genes, with relevance to neurodevelopmental disorders.

Investigating noncoding RNAs for an association with ASD or SCZ CNV loci

We investigated the overlap between 908 enhancer-ncRNAs (Supplementary table S8), and CNVs associated with Autism Spectrum Disorder (ASD) and Schizophrenia (SCZ). For ASD CNV associations, we utilised our recently reported tool SNATCNV [22] to identify high-confidence CNV loci in a cohort of 19,663 autistic and 6,479 non-autistic individuals (http://autism.mindspec.org/autdb; download date: July 2018), we mapped enhancer ncRNAs to loci for 3,260 deletion and 4,642 duplication
regions, respectively (99% confidence, P-value threshold of 0.001; see Methods section). A full list of ASD associated CNVs identified by SNATCNV is provided in Supplementary table S11. For our investigation of enhancer-ncRNA associations with CNV loci for Schizophrenia, we performed SNATCNV analysis on a cohort of 21,210 SCZ individuals in which 262 deletion and 138 duplication loci were identified, respectively (Supplementary table S12). For each dataset, we identified enhancer-ncRNAs that overlap with ASD- or SCZ-associated CNVs, defined as loci with at least 10% positional overlap; see Methods section). Of the 908 enhancer ncRNAs analysed, we found 154 ncRNAs (17%) that were associated with ASD comprising 56 CNV deletion and 98 CNV duplication loci. In all, 9 ncRNAs (1%) are identified for SCZ in this investigation, comprising seven deleted and two duplicated CNVs (Supplementary table S13). We also performed the analysis on 17,743 noncoding genes (with at least one nervous system related eQTL polymorphism) (Supplementary table S2). We found that 2,572 noncoding genes (14.5%) overlap with at least one ASD-associated CNVs (including 936 deletions and 1,636 duplications). For schizophrenia, there were 167 ncRNAs (0.94%) including 122 associated with CNV deletions and 45 associated with CNV duplications types. When considering all 60,681 noncoding genes, we identified 8,787 (14.5%, including 2,577 deletions and 6,210 duplications) for ASD CNVs and 348 (0.57% including 269 deletions and 79 duplications) for schizophrenia. Thus, enhancer ncRNAs are more highly associated with CNV loci for ASD, compared to schizophrenia.

Enhancer ncRNAs are associated with CNV loci for ASD and SCZ, and influence novel downstream genomic loci in different ways

From this analysis, we found that for two noncoding genes CATG00000042190 and CATG00000104381 (out of 154 noncoding genes related to ASD), their eQTL associated coding genes (OR2W3 and GDI2 linked with ncRNAs CATG00000042190 and CATG00000104381, respectively) do not map to CNV loci. Furthermore, we found that only one ncRNA (CATG00000042190) maps to an ASD CNV whereas its eQTL-associated gene does not implicate an NDD CNV, and its eQTL gene (OR2W3) does not have another reported interaction through any eQTL from ASD CNV data (Table 4). This suggests that the enhancer-ncRNAs CATG00000042190 and CATG00000104381 are unique in their association with ASD, while their regulatory
actions lie in downstream loci that have not previously been associated with this condition. In addition, for 268 of 908 enhancer ncRNAs, we find an association with NDD-related GWAS SNPs or ASD/SCZ associated CNVs (Supplementary table S13). Interestingly, for 82 of these, the eQTL associated coding gene does not overlap with either NDD related GWAS SNPs or ASD/SCZ associated CNVs (Supplementary table S14), suggesting the genomic variant in the enhancer-ncRNA may influence the expression of eQTL linked gene. Importantly, for 23 of 82 the eQTL linked coding gene does not overlap with GWAS/CNV, and also has no eQTL interaction with another coding or noncoding genes, including 14 enhancer-ncRNAs in SCZ and 9 enhancer-ncRNAs in other NDD associated genes (Table 4). These enhancer-ncRNAs are notable for their unique features. For example, CTB-180A7.8 is a long noncoding RNA located on chr19:6393588-6411788. There are robust signals for HMM predicted enhancers, H3K27ac, H3K4me1 histone active marks, and DNase I hypersensitive sites overlapped with CTB-180A7.8. This brain-enriched IncRNA (brain-enriched expression P-value: 1.08e-73) is linked with gene ALKBH7 through an eQTL link (Figure 4). Importantly, this IncRNA encompasses an ASD related GWAS SNP (rs6510896), and also lies within a region which is significantly deleted in ASD cases compared to controls (Figure 4). Of note, ALKBH7 has not yet been associated with NDD related disorders, yet our findings suggest that enhancer-like activity of CTB-180A7.8 for ALKBH7, as well as mutation or deletion in IncRNA CTB-180A7.8 may be relevant to ALKBH7 expression in neurodevelopment, and NDDs such as ASD.

In another example, the IncRNA CATG00000053385 (chr20:45035426-45084326) interacts with the gene SLC12A5 through an eQTL link. SLC12A5 encodes potassium and chloride co-transporter 2 (KCC2), and is the main extruder of chloride in neurons that mediates the electrophysiological effects of GABA signalling [23]. Based on our observations, CATG00000053385 may be relevant to modulation of SLC12A5 expression, leading to NDDs, as follows. CATG00000053385 overlaps with strong signals of HMM enhancers and histone active marks H3K27ac, H3K4me1, and DNase I hypersensitive sites, as detected in brain tissue analyses (Figure 5). Furthermore, this IncRNA is associated with two SCZ GWAS SNPs and one ASD related GWAS SNP (Figure 5), is significantly expressed in brain (brain-enriched expression P-value: 9.61e-09), and dynamically expressed in an induced pluripotent stem cell model of neuron differentiation. Collectively, these observations indicate that
CATG00000053385 is relevant to SLC12A5 enhancer activity, and mutation in this IncRNA is associated with NDDs including ASD and schizophrenia.

It is further noteworthy that 3 of 23 IncRNA genes are associated with related GWAS SNPs for both SCZ and NDDs, namely STX18-AS1, CTC-467M3.1, and CASC17. In the case of STX18-AS1, this IncRNA is located on human chromosome 4, and shows reduced expression in association with rs6824295, a SNP associated with heart disease [24], as well as rs16835979, whose clinical significance is unknown. Also, an eQTL polymorphism in STX18-AS1 is associated with the coding gene EVC, yet we find no overlap of neither NDD related GWAS nor CNV associated with this coding gene. Interestingly, we identified two NDD related GWAS SNPs (rs2887447 and rs13130037) and one schizophrenia related GWAS SNP (rs7675915) overlapping with STX18-AS1, and also that STX18-AS1 is significantly duplicated in individuals with Schizophrenia. Thus, mutations in the ncRNA STX18-AS1 is relevant to EVC expression in NDDs. In the second example, CTC-467M3.1 is a IncRNA located in chromosome 5, and is also known as MEF2C antisense RNA 2 (MEF2C-AS2). Although there is not any strong evidence for this gene to be involved in NDD or schizophrenia diseases, this gene is critical to neurodevelopment, learning and memory [25]. For example, MEF2C participates in a brain gene co-expression network which showed a promising therapeutic tool to persuade cognitive enhancement [26–28]. Finally, in the third example, the Cancer Susceptibility Candidate 17 (CASC17) is a non-protein-coding gene in chromosome 17 of the human genome. It was shown that genetic variants of CASC17 gene could affect the risk for psychosis [29]. The CASC17 gene also correlated with reactionary and impulsive behavior, given its characterisation as a high confidence candidate based on multiple SNPs identified through a genome-wide approach for children's aggressive behavior [30].

**Association of enhancer ncRNAs with DECIPHER phenotypes**

To better understand whether enhancer ncRNAs identified in this study are significantly associated with behavioural traits, we cross-correlated our results with patient phenotypes documented in DECIPHER (Database of Chromosomal Imbalance and Phenotype in Humans using Ensembl Resources) [31]. DECIPHER contains 1,094 patients annotated as autistic, 5,558 patients annotated with intellectual disability (552
both annotated as intellectual disability and NDD) and 6,513 patients with other phenotypes. To achieve this, we began by enumerating phenotypic terms in DECIPHER patients, with CNVs implicated in our 82 enhancer-ncRNAs (enhancer-ncRNAs that contain NDD related GWAS SNPs or CNVs but the eQTL linked gene does not contain NDD related GWAS SNPs or CNVs) which do not overlap with eQTL linked coding genes. The frequencies for pairs of enhancer-ncRNAs associated with a given DECIPHER phenotype were then calculated, to derive the proportion of DECIPHER patients with such criteria. To assess significance, we used 5,000 random permutations of the patient-phenotype associations in DECIPHER to estimate the fraction of patients with the same enhancer ncRNAs-phenotype pair that emerges by chance. Using this approach, we found 246 patients in DECIPHER where CNV overlapped with at least one of our enhancer ncRNAs, while the eQTL linked gene did not overlap with the CNV.

When we looked at this data further, we identified 48 enhancer ncRNAs (48 of 82 enhancer-ncRNAs), with at least one phenotype term over-represented (95% confidence interval in DECIPHER patients with CNVs overlapping the enhancer ncRNAs (Supplementary table S15). For 34 of enhancer-ncRNAs we identified at least three DECIPHER patients with CNVs overlapping the enhancer ncRNAs (Supplementary table S17). For example, enhancer ncRNA ERICH1-AS1 is interacting with coding gene FBXO25, which has been associated to psychiatric phenotypes (PMID: 31849056). We found both NDD and SCZ related GWAS mutations in ERICH1-AS1 but not in FBXO25. Our DECIPHER analysis revealed 13 samples in the DECIPHER database with CNVs that encompassed our candidate ncRNAs ERICH1-AS1 and did not overlap with eQTL linked coding genes FBXO25. Interestingly, phenotypic terms Autism, Intellectual Disability, and Macrocephaly were enriched for DECIPHER patients with CNV overlapping with ERICH1-AS1 (Supplementary table S17). Another example is enhancer-ncRNA SYN2. Nervous system related eQTL data shows that this ncRNA interacts with protein-coding gene PPARG. Our literature search showed that still there is no a consensus about the function of PPARG in NDD/SCZ disorders (PMID: 29229843, PMID: 19560328). However, we found SYN2 as a potential enhancer for PPARG that contains NDD related GWAS mutation. Interestingly, we found seven samples in the DECIPHER database with CNVs that encompassed our candidate ncRNAs SYN2 and did not
overlap with eQTL linked coding genes PPARG. The DECIPHER analysis also revealed that HPO terms “Delayed Speech and Language Development”, “Seizures”, and “Abnormality of the Ear” were enriched within these seven DECIPHER patients. This would suggest that genomic variant in SYN2 may be responsible for the functionality of PPARG in NDD/SCZ disorders. Thus, for these enhancer-RNAs, we find unique associations with known neurodevelopmental genes, as well as previously uncharacterised candidates.

Investigating the impact of 82 enhancer-ncRNAs for functions in neurodevelopment and NDDs

Our investigation has led to the identification of 82 enhancer ncRNAs with an association with NDD related GWAS SNP or ASD/SCZ CNV, and which have eQTL-associated coding genes that do not overlap with neither NDD-related GWAS SNPs nor ASD/SCZ CNV loci (Supplementary table S14). When we conducted a literature search for evidence to support the hypothesis that these enhancer-ncRNAs influence gene expression relevant to nervous system development and NDDs, we identified four notable examples, as follows.

In the first example, we identify MALAT1 (Metastasis Associated Lung Adenocarcinoma Transcript 1) as an NDD-related enhancer-ncRNA, located within chromosome 11 with 12.7kb in length; this lncRNA is highly expressed in neurons [32]. It has been shown that the loss of the MALAT1 negatively affects the expression of neighboring genes, including genes which are significantly decreased in expression within several brain regions relevant to schizophrenia [33]. Furthermore, a study reported that MALAT1 expression was significantly different in patients with schizophrenia compared with healthy subjects [34], and MALAT1 is also implicated in ASD [35]. In addition, the brain eQTL data shows MALAT1 has an interaction with a protein-coding gene (AP000769.1), although AP000769.1 is associated with bone mineral density [36], while its function with NDDs is uncharacterised.

In the second example, we find that SYN2 (Synapsin II) is a candidate gene for NDD which is influenced by enhancer-ncRNAs. This gene is 253.9kb in length and located in chromosome 3, and is a member of the synapsin gene family. One of its variants belongs to a noncoding gene class. SYN2 is associated with abnormality of
the nervous system through the GWAS data [37], and its association with schizophrenia is reported in several studies, particularly in families of Northern European ancestry [38]–[40]. Studies also indicate that SYN2 loss-of-function may be associated with autism, abnormal behavior, and epilepsy in humans, and in comparable neuropathological features observed in mice [37]. SYN2 interacts with four different protein-coding genes (PPARG, TIMP4, RAF1, and CAND2), as indicated in the brain eQTL data. Yet, for PPARG, its association with schizophrenia remains to be clarified, owing to conflicting results [41], [42]. Also, there is evidence that PPARG is associated with early postnatal neurodevelopmental disease and cerebral connectivity [43], [44]. In the case of TIMP4, this gene is associated with both ASD and schizophrenia [45]. Similarly, RAF1 and CAND2 are implicated in NDD and schizophrenia [46]–[49].

The third example of an enhancer-ncRNA with unique features is SOX2-OT (SOX2 overlapping transcript (SOX2OT)). This lncRNA is 847.1 kb in length, located in chromosome 3 and comprises at least 5 exons. Our analysis showed that there are nine GWAS SNPs associated schizophrenia within SOX2-OT. It is an important regulator of neurogenesis and is dynamically expressed during neural cell differentiation [50], and SOX2OT is associated with schizophrenia, as reported in a study of 108 schizophrenia-associated genetic loci [51], [52]. In addition, it has been shown that SOX2OT is relevant to ASD as well [53], [54]. Based on the brain eQTL data, SOX2OT interacts with two protein-coding genes (CCDC39 and FXR1), of which CCDC39 is associated with schizophrenia [52], while FXR1 may be relevant in mental conditions [55], [56].

The fourth example of an enhancer-ncRNA for NDD is ATXN8OS (Ataxin 8 opposite strand (ATXN8OS)), a lncRNA gene 23.7 kb in length, and located in chromosome 13. This gene is associated with cognitive impairment in a GWAS SNP study [57], and is implicated in schizophrenia through a study with the GeneAnalytics program [58]. Furthermore, ATXN8OS is suggested to be relevant to neurodegenerative diseases through dysregulation of gene expression [59], [60]. ATXN8OS interacts with a protein-coding gene KLHL1 based on the brain eQTL data, and KLHL1 is associated with gait disturbance, a motor phenotype affecting some individuals with ASD [61]. Furthermore, KLHL1 is reported to have a co-expressed interaction with TSHZ3 gene which itself is associated with ASD [62]. Also, KLHL1 is
implicated in Asperger Syndrome, based on a GWAS study [63]. Taken together, we find that enhancer-ncRNAs influence a wide range of known and previously uncharacterised genes to modulate neurodevelopment and NDDs.

**Discussion**

We developed an integrative bioinformatics pipeline to systematically analyse and identify noncoding RNAs with possible enhancer role in NDDs. Our pipeline analysed a large set of ncRNAs through a workflow which integrated ENCODE regulatory features, FANTOM5 expression profiles, and nervous system related eQTL pairs to identify 908 ncRNAs as putative enhancers in NDDs. The 908 ncRNAs were then further evaluated with neurodevelopmental associated GWAS SNPs and Copy Number Variations to identify those putative ncRNA enhancers that significantly deleted/mutated or duplicated in neurodevelopmental samples against healthy individuals. Through this approach, we identified 82 putative ncRNA enhancers that contained NDD related genomic variants (GWAS SNP or CNV) and interact with eQTL-linked genes, but that no genomic variants overlapping with eQTL-linked genes. We called these putative ‘enhancer ncRNAs’. Interestingly, of these enhancer ncRNAs, for 23 of them, the noncoding-RNA is the only region interacting with the eQTL-linked gene. It suggests that deletion or duplication in these ncRNAs may affect the expression of the eQTL linked gene. Of 82 enhancer ncRNAs, our systematic literature search revealed that 18 ncRNAs are associated with neurodevelopmental disorders, while 15 are associated with schizophrenia. Furthermore, expression of 39 of the 82 enhancer ncRNAs are stimulated in an induced pluripotent stem cell model of neuron differentiation, suggesting their relevance to neurodevelopment. Our literature search further revealed that 28 of the 144 eQTL linked coding genes (after duplications removed) interacting with the 82 enhancer ncRNAs are NDD associated genes (Supplementary table S16). Hence, of these, we report the remaining 116 coding genes as novel NDD candidate genes which are associated with enhancer-ncRNAs.

One interpretation of our findings is that genomic variation in a noncoding RNA or its eQTL-mapped enhancer loci influences expression of downstream target genes enriched in brain tissues, leading to NDD. Of note, we find that enhancer-ncRNAs, and their corresponding eQTL are brain-enriched. Also, eQTL-linked coding genes (74 of
163 eQTL coding genes interacting with the ncRNAs) are also brain-enriched. Co-expression of these genes with ncRNAs harboring NDD-associated mutations may suggest that the noncoding RNAs are involved in similar biological functions and are potential candidate NDD risk loci. For example, the ncRNA CATG00000070525 (chr4:149,363,864-149,495,900) interacts with brain-enriched coding gene NR3C2. The NR3C2 is a member of a family of nuclear receptors in which their ligands diffuse into cells, interacts with their cognate receptor to signal gene expression changes within the nucleus. This brain-enriched gene is classified by SFARI gene as category 3 ‘Suggestive Evidence’ ASD candidate genes. As a corollary, mutation of the mouse ortholog nr3c2 leads to nervous system phenotypes [64]. Also, our analysis of DECIPHER data found one DECIPHER sample with CNV deletion that overlaps with CATG00000070525 did not overlap with eQTL-linked coding gene NR3C2. Thus, our investigation has identified a role for CATG00000070525 to influence NR3C2 in NDD.

By profiling post mortem brains (from 48 ASD, 49 controls) Parikshak et al. [65] identified 60 lincRNAs based on dysregulated expression, and not mutation in ASD patients, which may play a role in ASD, but are not causal genes per se. We analysed these data to find that only one of the reported lincRNAs from this study, the lincRNA ENSG00000271913, lies within an ASD CNV region, or contains an ASD-related GWAS SNPs. Yet, the relevance of ENSG00000271913 in ASD is confounded by the finding that it is recurrently co-deleted with SHANK3, a well-characterised ASD causal gene [66]. Of note, our brain-enriched enhancer-ncRNAs are significantly detected in NDD individuals with deletion/duplication or GWAS SNPs. it suggests disruption of interaction between these ncRNAs with eQTL-linked genes are most likely to be candidate for the observed phenotype.

Finally we interrogated the DECIPHER database [31] to identify patients with genomic abnormalities in the enhancer ncRNAs but not in the eQTL-linked genes. For 79 of 161 interactions (eQTL interaction enhancer-ncRNAs and eQTL coding genes), we identified candidates in which there was at least one DECIPHER sample in which a genomic abnormality is observed in the enhancer-ncRNAs, but not in the eQTL-linked genes. This led to the identification of 34 interactions, of which there were at least 3 patients for each (Supplementary table S17). Consistent with a role for our set of enhancer-ncRNAs in NDD, this analysis led us to identify overrepresented traits including autistic behavior, delayed speech and language, cognitive impairment and
global developmental delay for 77 of the 79 DECIPHER samples. Our data therefore suggests that genomic variants in these enhancer ncRNAs are relevant to neurodevelopmental disorders, unique to their functions as modulators of enhancer activity. For 34 of the 82 enhancer ncRNAs, at least one phenotype term was overrepresented (fold enrichment above 2) in DECIPHER patients. Of note, the majority of these 34 noncoding RNAs had unique combinations of overrepresented phenotypes (73 combinations in total). Therefore, genomic abnormalities for enhancer ncRNAs are associated with distinct clinical phenotypes. The categorisation of these combinations of phenotypes for enhancer-ncRNAs in this study may be informative in the phenotypic characterisation of patients (e.g. obesity, microcephaly, macrocephaly, split hand). Importantly, for patients with genomic abnormalities in enhancer–ncRNAs we have identified in this study, the associated co-morbidities that we identify, such as renal cysts, atrial septal defects and tetralogy of Fallot, may be relevant for clinical consideration in NDD presentation.

Methods and Materials

CNV data

For the CNV region discovery, autism CNV data from 19,663 autistic patients (47,189 CNVs) and 6,479 normal individuals (24,888 CNVs) compiled from multiple large NDD CNV datasets by the Simons Foundation Autism Research Initiative (SFARI) was downloaded (http://autism.mindspec.org/autdb; download date: July 2016). Schizophrenia CNV data from 27,034 schizophrenia and 25,448 control individuals where obtained from the Marshall et al. study [67] (downloaded from the European Genome-Phenome Archive with accession number EGAS00001001960).

Gene list

We have combined two genes list from FANTOM5 [16] and Ensemble [68] consortia (genome building hg19). This enables us to have a comprehensive list of noncoding genes. An in-house script has been used to combine the lists based on gene coordinates and/or gene names. The combined list can be found in the Supplementary Table S18). In total, 84,065 genes are available in the final list
including 60,681 noncoding genes. Figure 2 shows distribution of different types of noncoding genes in the list.

Identification of genes with nervous system enriched expression

We used the list of brain-enriched genes in our previous paper [22]. In summary, to determine whether a gene had enriched expression in the 101 nervous system samples profiled by the FANTOM5 consortium (compared to the total set of 1,829 samples profiled by FANTOM), we first ranked samples by expression and then selected the top 101 samples most highly expressing the gene. We then used Fisher’s exact test to determine a P-value indicating whether the top 101 samples were more likely to be nervous system samples or not. To determine a threshold on the P-value we carried out 50,000 permutations randomising the sample labels to determine P-value thresholds at the 99% confidence interval; any gene with a P-value better than this permutation-specific P-value threshold, we consider a significantly nervous system-enriched gene.

ChromHMM predicted promoter and enhancer regions

We have downloaded ChromHMM predicted promoters and enhancers from the ENCODE project [69]. First, we have used an in-house script in order to explore ChromHMM results for each gene. However, there are eight different ChromHMM dataset from human brain tissue samples. So, we used the consensus term of the eight ChromHMM that overlapped with a gene. For each region, ChromHMM data could be the following terms: active TSS, flanking active TSS, transcr at gene 5’ and 3’, strong transcription, weak transcription, genic enhancers, enhancers, ZNF genes repeats, heterochromatin, bivalent poised TSS, flanking bivalent TSS, bivalent enhancer, repressed polycomb, weak repressed polycomb, and quiescent low. We have used the maximum repeated term (from eight different samples), as a consensus term for each gene. If more than one term is shown, all of the equivalent terms have been considered.

Overlapping between noncoding RNAs and eQTL pairs
eQTL data were downloaded from the Genotype-Tissue Expression (GTEx) Project [19] for thirteen different tissues of brain (Amygdala, Anterior Cingulate Cortex, Caudate Basal Ganglia, Cerebellar Hemisphere, Cerebellum, Cortex, Frontal Cortex, Hippocampus, Hypothalamus, Nucleus Accumbens Basal Ganglia, Putamen Basal Ganglia, Spinal Cord Cervical, Substantia Nigra). The total number of entries for each location is shown in Supplementary Table S19. We used an in-house script to find noncoding genes that encompass eQTL polymorphisms.

GWAS data

GWAS SNPs were downloaded from GWAS Catalog (https://www.ebi.ac.uk/gwas/docs/file-downloads) and GWASdb v2 (http://jjwanglab.org/gwasdb). We only considered those SNPs that were associated with phenotypes Abnormal Emotion/Affect Behavior, Abnormality of Metabolism, Abnormality of the Endocrine System, Abnormality of the Nervous System, Abnormality of the Skin, Attention Deficit Hyperactivity Disorder, Autistic Behavior, Cerebellar Hypoplasia, Cognitive Impairment, EEG Abnormality, Language Impairment, Psychosis, and Schizophrenia.

Annotate noncoding RNAs with GWAS using PLINK

As GWAS SNPs were reported using different genome build versions hg19 and hg38, we first converted all GWAS SNP coordinates to UCSC hg19 using UCSC Lift Genome Annotations tools [70] and confirmed the locations with NCBI remap tools (www.ncbi.nlm.nih.gov/genome/tools/remap). An in-house script has then been used to combine both datasets based on gene coordinates and/or gene names. The combined GWAS list can be found in Supplementary table S20. In order to perform a GWAS annotation analysis using PLINK [71] it is needed to prepare three files; an association file (based on our GWAS list), an attribution file downloaded from dbSNP (build 129), and a gene list file (created based on our gene list). We have also considered ±1Kbp distance from a gene as well.

Using SNATCNV to identify CNVs associated with NDD
We used SNATCNV to identify significantly deleted or duplicated CNVs in NDD and SCZ cohorts. In summary, to identify regions that are significantly more often deleted or duplicated in autism patients than in phenotypically normal individuals, SNATCNV counts, for every position in the genome, how often the base was either deleted or duplicated in the case and control CNVs. Fisher's exact test is then used to determine whether the base was significantly more frequently observed in a duplicated or deleted region of cases or controls. To determine the significance of this association SNATCNV used permutation testing by randomising 500,000 permutations for a range of observed CNV frequencies. In this study, we defined 'significant regions' as those with P-values better than 0.001, corresponding to 99% confidence. We next performed the same analysis to identify significantly deleted or duplicated CNVs in SCZ cohort. We then considered genes as deleted or duplicated if they had at least 10% overlap with the significant NDD associated CNVs.

Annotation of known and putative novel NDD associated genes

For the candidate ncRNAs annotated as putative enhancer identified in this study, we carried out a comprehensive literature search of all genes that are interacting with the noncoding RNAs. For the extended literature search, we specifically searched for "gene name + autism" or "gene name + NDD" (e.g. SAMD11 + autism or SAMD11 + NDD), or "gene name + enhancer". As a result, if a gene had a previous enhancer casual association, it was labelled as 'there is a known enhancer'.

Author contributions

HAR designed the study; HAR, YA, and JI-TH wrote the manuscript; HAR, JI-TH, YA, ARRF, and NL edited the manuscript. YA and HAR carried out all the analyses including the statistical analyses, region identification, text mining, eQTL pair analysis, GWAS, DECIPHER, and gene ontology. HAR and YA curated the genes and regions. YA created figures 1, 2 and all tables except tables S11, S12, S15, S16, S17, S19, S20. HAR generated figures 3, 4, and 5 and tables S11, S12, S15, S16, S17, and S19. All authors have read and approved the final version of the paper.
Ethics approval and consent to participate

NA

Availability of data and materials

All data are publicly available and cited in the paper.

Consent for publication

All authors have read and approved the final version of the paper.

Conflict of interest

The authors declare no competing financial/non-financial interests.

Funding

HAR is supported by UNSW Scientia Fellowship and is a member of the UNSW Graduate School of Biomedical Engineering. ARRF is supported by an Australian National Health and Medical Research Council Fellowships APP1154524. This work was supported by a grant to JI-TH and ARRF from the Telethon-Perth Children’s Hospital Research Fund, an Australian Research Council Discovery Project grant (DP160101960) to ARRF, funds raised by the UNSW Scientia Fellowship to HAR, as well as laboratory startup funds to JI-TH from Curtin University.

Declaration

Declare in any published work that those who carried out the original analysis and collection of the Data bear no responsibility for the further analysis or interpretation of the data.

Acknowledgments
We kindly acknowledge Government of Western Australia, Department of Health, Clinical Excellence, for their support of this project through MERIT award to HAR. This study makes use of data generated by the DECIPHER community. A full list of centres who contributed to the generation of the data is available from https://decipher.sanger.ac.uk/about/stats and via email from decipher@sanger.ac.uk.

Funding for the DECIPHER project was provided by Wellcome.

References

[1] A. R. Cardoso et al., “Essential genetic findings in neurodevelopmental disorders,” Human genomics. 2019.

[2] A. Gupta, L. H. Tsai, and A. Wynshaw-Boris, “Life is a journey: A genetic look at neocortical development,” Nature Reviews Genetics. 2002.

[3] D. J. Miller, A. Bhaduri, N. Sestan, and A. Kriegstein, “Shared and derived features of cellular diversity in the human cerebral cortex,” Current Opinion in Neurobiology. 2019.

[4] Z. Molnár et al., “New insights into the development of the human cerebral cortex,” Journal of Anatomy. 2019.

[5] E. Courchesne, T. Pramparo, V. H. Gazestani, M. V. Lombardo, K. Pierce, and N. E. Lewis, “The ASD Living Biology: from cell proliferation to clinical phenotype,” Molecular Psychiatry. 2019.

[6] T. R. Cech and J. A. Steitz, “The noncoding RNA revolution - Trashing old rules to forge new ones,” Cell. 2014.

[7] R. Z. He, D. X. Luo, and Y. Y. Mo, “Emerging roles of IncRNAs in the post-transcriptional regulation in cancer,” Genes and Diseases. 2019.

[8] O. M. Rennert and M. N. Ziats, “Editorial: Non-coding RNAs in neurodevelopmental disorder,” Frontiers in Neurology. 2017.

[9] S. Banerjee-Basu, E. Larsen, and S. Muend, “Common microRNAs Target Established ASD Genes,” Front. Neurol., 2014.

[10] M. L. Bortolin-Cavaillé and J. Cavaillé, “The SNORD115 (H/MBII-52) and SNORD116 (H/MBII-85) gene clusters at the imprinted Prader-Willi locus generate canonical box C/D snoRNAs,” Nucleic Acids Res., 2012.

[11] M. Alders, J. Bliek, K. vd Lip, R. vd Bogaard, and M. Mannens, “Determination of KCNQ1OT1 and H19 methylation levels in BWS and SRS patients using methylation-sensitive high-resolution melting analysis,” Eur. J. Hum. Genet., 2009.

[12] V. Faundez, M. Wynne, A. Crocker, and D. Tarquinio, “Molecular systems biology of
neurodevelopmental disorders, rett syndrome as an archetype," *Front. Integr. Neurosci.*, 2019.

675 [13] B. B. Misra, C. Langefeld, M. Olivier, and L. A. Cox, “Integrated omics: tools, advances and future approaches,” *J. Mol. Endocrinol.*, 2018.

677 [14] M. R. Smith *et al.*, “Integrative bioinformatics identifies postnatal lead (Pb) exposure disrupts developmental cortical plasticity,” *Sci. Rep.*, 2018.

679 [15] A. Maes *et al.*, “MinOmics, an Integrative and Immersive Tool for Multi-Omics Analysis,” *J. Integr. Bioinform.*, 2018.

681 [16] C. C. Hon *et al.*, “An atlas of human long non-coding RNAs with accurate 5′ ends,” *Nature*, 2017.

683 [17] V. Emilsson *et al.*, “Genetics of gene expression and its effect on disease,” *Nature*, 2008.

684 [18] E. E. Schadt *et al.*, “Genetics of gene expression surveyed in maize, mouse and man,” *Nature*, 2003.

686 [19] K. G. Ardlie *et al.*, “The Genotype-Tissue Expression (GTEx) pilot analysis: Multitissue gene regulation in humans,” *Science (80-. ).*, 2015.

688 [20] A. R. R. Forrest *et al.*, “A promoter-level mammalian expression atlas,” *Nature*, 2014.

689 [21] F. W. Albert and L. Kruglyak, “The role of regulatory variation in complex traits and disease,” *Nature Reviews Genetics*. 2015.

691 [22] H. Alinejad-Rokny, J. I. T. Heng, and A. R. R. Forrest, “Brain-enriched coding and long non-coding RNA genes are overrepresented in recurrent autism spectrum disorder CNVs,” *bioRxiv*, p. 539817, Jan. 2019.

694 [23] R. Tao *et al.*, “Transcript-specific associations of SLC12A5 (KCC2) in human prefrontal cortex with development, schizophrenia, and affective disorders,” *J. Neurosci.*, 2012.

696 [24] H. J. Cordell *et al.*, “Genome-wide association study of multiple congenital heart disease phenotypes identifies a susceptibility locus for atrial septal defect at chromosome 4p16,” *Nat. Genet.*, 2013.

699 [25] A. C. Barbosa *et al.*, “MEF2C, a transcription factor that facilitates learning and memory by negative regulation of synapse numbers and function,” *Proc. Natl. Acad. Sci. U. S. A.*, 2008.

701 [26] A. J. Harrington *et al.*, “MEF2C regulates cortical inhibitory and excitatory synapses and behaviors relevant to neurodevelopmental disorders,” *Elife*, 2016.

703 [27] B. L. Gudenas and L. Wang, “Gene coexpression networks in human brain developmental transcriptomes implicate the association of long noncoding RNAs with intellectual disability,” *Bioinform. Biol. Insights*, 2015.

706 [28] A. C. Mitchell *et al.*, “MEF2C transcription factor is associated with the genetic and epigenetic risk architecture of schizophrenia and improves cognition in mice,” *Mol. Psychiatry*, 2018.

708 [29] D. Avramopoulos *et al.*, “Infection and inflammation in schizophrenia and bipolar disorder: A
H. V. Firth et al., “DECIPHER: Database of Chromosomal Imbalance and Phenotype in Humans Using Ensembl Resources,” Am. J. Hum. Genet., 2009.

H. Fallah, I. Azari, S. M. Neishabouri, V. K. Oskooei, M. Taheri, and S. Ghafouri-Fard, “Sex-specific up-regulation of IncRNAs in peripheral blood of patients with schizophrenia,” Sci. Rep., 2019.

M. Maschietto et al., “Gene expression of peripheral blood lymphocytes may discriminate patients with schizophrenia from controls,” Psychiatry Res., 2012.

H. Fallah, M. Ganji, S. Arsang-Jang, A. Sayad, and M. Taheri, “Consideration of the role of MALAT1 long noncoding RNA and catalytic component of RNA-induced silencing complex (Argonaute 2, AGO2) in autism spectrum disorders: Yes, or no?,” Meta Gene, 2019.

M. E. Hauberg et al., “Large-Scale Identification of Common Trait and Disease Variants Affecting Gene Expression,” Am. J. Hum. Genet., 2017.

A. Corradi et al., “SYN2 is an autism predisposing gene: Loss-offunction mutations alter synaptic vesicle cycling and axon outgrowth,” Hum. Mol. Genet., 2014.

R. A. Tahir and S. A. Sehgal, “Pharmacoinformatics and Molecular Docking studies reveal potential novel compounds against Schizophrenia by target SYN II,” Comb. Chem. High Throughput Screen., 2018.

H. J. Lee et al., “Association study of polymorphisms in synaptic vesicle-associated genes, SYN2 and CPLX2, with schizophrenia,” Behav. Brain Funct., 2005.

V. Saviouk, M. P. Moreau, I. V. Tereshchenko, and L. M. Brzustowicz, “Association of synapsin 2 with schizophrenia in families of Northern European ancestry,” Schizophr. Res., 2007.

I. Martinez-Gras et al., “The anti-inflammatory prostaglandin 15d-PGJ2 and its nuclear receptor PPARgamma are decreased in schizophrenia,” Schizophr. Res., 2011.

A. Mathur, M. H. Law, T. Hamzehloei, I. L. Megson, D. J. Shaw, and J. Wei, “No association between the PPARG gene and schizophrenia in a British population,” Prostaglandins Leukot. Essent. Fat. Acids, 2009.

F. J. Torres-Espínola et al., “Maternal PPARG Pro12Ala polymorphism is associated with infant’s neurodevelopmental outcomes at 18months of age,” Early Hum. Dev., 2015.

M. L. Krishnan et al., “Machine learning shows association between genetic variability in PPARG and cerebral connectivity in preterm infants,” Proc. Natl. Acad. Sci. U. S. A., 2017.
S. V. Yim et al., “Assessment of the correlation between TIMP4 SNPs and schizophrenia and autism spectrum disorders,” Mol. Med. Rep., 2013.

A. Prasad et al., “A Discovery resource of rare copy number variations in individuals with autism spectrum disorder,” G3 Genes, Genomes, Genet., 2012.

M. C. Holter et al., “The Noonan Syndrome-linked Raf1L613V mutation drives increased glial number in the mouse cortex and enhanced learning,” PLoS Genet., 2019.

B. Adviento et al., “Autism traits in the RASopathies,” J. Med. Genet., 2014.

W. Warnica et al., “Copy number variable micromas in schizophrenia and their neurodevelopmental gene targets,” Biol. Psychiatry, 2015.

P. P. Amaral et al., “Complex architecture and regulated expression of the Sox2ot locus during vertebrate development,” RNA, 2009.

R. M. Xavier, A. Vorderstrasse, R. S. E. Keefe, and J. R. Dungan, “Genetic correlates of insight in schizophrenia,” Schizophr. Res., 2018.

S. Ripke et al., “Biological insights from 108 schizophrenia-associated genetic loci,” Nature, 2014.

T. C. Roberts, K. V. Morris, and M. J. A. Wood, “The role of long non-coding RNAs in neurodevelopment, brain function and neurological disease,” Philosophical Transactions of the Royal Society B: Biological Sciences. 2014.

J. Tang, Y. Yu, and W. Yang, “Long noncoding RNA and its contribution to autism spectrum disorders,” CNS Neuroscience and Therapeutics. 2017.

J. Khlghatyan et al., “Mental illnesses-associated Fxr1 and its negative regulator Gsk3b are modulators of anxiety and glutamatergic neurotransmission,” Front. Mol. Neurosci., 2018.

J. Khlghatyan and J.-M. Beaulieu, “Are FXR Family Proteins Integrators of Dopamine Signaling and Glutamatergic Neurotransmission in Mental Illnesses?,” Front. Synaptic Neurosci., 2018.

A. Lilja, P. Hämäläinen, E. Kaitaranta, and R. Rinne, “Cognitive impairment in spinocerebellar ataxia type 8,” J. Neurol. Sci., 2005.

T. Sundararajan, A. M. Manzardo, and M. G. Butler, “Functional analysis of schizophrenia genes using GeneAnalytics program and integrated databases,” Gene, 2018.

J. D. Kohtz and E. G. Berghoff, “Regulatory long non-coding RNAs and neuronal disorders,” Physiol. Behav., 2010.

C. Fenoglio, E. Ridolfi, D. Galimberti, and E. Scarpini, “An emerging role for long non-coding RNA dysregulation in neurological disorders,” International Journal of Molecular Sciences, 2013.

Y. He, T. Zu, K. A. Benzow, H. T. Orr, H. B. Clark, and M. D. Koob, “Targeted deletion of a single Sca8 ataxia locus allele in mice causes abnormal gait, progressive loss of motor
coordinated, and Purkinje cell dendritic deficits,” *J. Neurosci.*, 2006.

[62] X. Caubit et al., “TSHZ3 deletion causes an autism syndrome and defects in cortical projection neurons,” *Nat. Genet.*, 2016.

[63] V. Warrier et al., “A pooled genome-wide association study of asperger syndrome,” *PLoS One*, 2015.

[64] M. C. Zennaro, A. Souque, S. Viengchareun, E. Poisson, and M. Lombès, “A new human MR splice variant is a ligand-independent transactivator modulating corticosteroid action,” *Mol. Endocrinol.*, 2001.

[65] N. N. Parikshak et al., “Genome-wide changes in IncRNA, splicing, and regional gene expression patterns in autism,” *Nature*, 2016.

[66] C. M. Durand et al., “Mutations in the gene encoding the synaptic scaffolding protein SHANK3 are associated with autism spectrum disorders,” *Nat. Genet.*, 2007.

[67] C. R. Marshall et al., “Contribution of copy number variants to schizophrenia from a genome-wide study of 41,321 subjects,” *Nat. Genet.*, 2017.

[68] F. Cunningham et al., “Ensembl 2019,” *Nucleic Acids Res.*, 2019.

[69] I. Dunham et al., “An integrated encyclopedia of DNA elements in the human genome,” *Nature*, 2012.

[70] “browser Ug. UCSC Lift Genome Annotations tools 2017,” Available from www.genome.ucsc.edu/cgi-bin/hgLiftOver.

[71] S. Purcell et al., “PLINK: a tool set for whole-genome association and population-based linkage analyses,” *Am. J. Hum. Genet.*, vol. 81, no. 3, pp. 559–575, Sep. 2007.

[72] S. Khakmardan, M. Rezvani, A. A. Pouyan, M. Fateh, and H. Alinejad-Rokny, “MHiC, an integrated user-friendly tool for the identification and visualization of significant interactions in Hi-C data,” *BMC Genomics*, 2020.

### Tables

**Table 1:** List of different noncoding RNAs fractions for every eQTL types (ncRNAs which contain at least one nervous system related eQTL polymorphism)

| Noncoding eQTL Type | IncRNA (%) | Pseudogene (%) | mRNA (%) | Antisense (%) | Sense overlapping (%) | miR RNA (%) | snoRNA (%) | snRNA (%) | rRNA (%) | 3prime overlapping (%) | tRNA (%) | Other (%) |
|---------------------|------------|----------------|----------|---------------|-----------------------|-------------|------------|-----------|---------|------------------------|---------|-----------|
| Cerebellum          | 66.1       | 19.8           | 0.4      | 4.9           | 2.3                   | 0.7         | 0.3        | 0.3       | 0.1     | 0                      | 0       | 4.9       |
### Table 2. List of neurodevelopmental disorders related GWAS that overlapped with the enhancer noncoding genes.

| Disease                                      | Number of GWAS | %  |
|----------------------------------------------|-----------------|----|
| Abnormal emotion/affect behavior             | 2               | 2.2|
| Abnormality of metabolism                    | 1               | 1.1|
| Abnormality of the endocrine system          | 1               | 1.1|
| Abnormality of the nervous system            | 7               | 7.9|
| Abnormality of the skin                      | 0               | 0.0|
| Attention deficit hyperactivity disorder     | 9               | 10.1|
| Autistic behavior                            | 2               | 2.2|
| Cerebellar hypoplasia                        | 0               | 0.0|
| Cognitive impairment                         | 9               | 10.1|
| EEG abnormality                              | 0               | 0.0|
| Language impairment                          | 1               | 1.1|
| Psychosis                                    | 10              | 11.2|
| Schizophrenia                                | 68              | 76.4|
| More than two disorders                      | 20              | 22.5|

### Table 3: Summary of the GWAS/CNV overlapping analysis for enhancer ncRNAs.

| # enhancer-ncRNAs contain GWAS/CNV | # enhancer-ncRNAs that overlap with GWAS/CNV and eQTL genes do not overlap with GWAS/CNV | # enhancer-ncRNAs that overlap with GWAS/CNV, eQTL genes do not overlap with GWAS/CNV, and eQTL genes have not another interaction |
|-----------------------------------|------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------|
|                                   | GWAS                                                                                     |                                                                                                                             |
| 12 different NDDs                 | 37*                                                                                       | 24*                                                                                                                         |
| Schizophrenia                     | 68*                                                                                       | 56*                                                                                                                         |
| 908                               |                                                                                          | 8 [STX18-AS1, RP11-679C8.2, CTC-467M3.1, RP11-660L16.2, RP1-34H18.1, CASC17, CATG0000036627.1, CTB-180A7.8] |
|                                  |                                                                                          | 14 [RP11-92G12.3, AC073479.1, STX18-AS1, CATG00000069256.1, CTC-467M3.1, CTB-1202.1, TRAF3IP2-AS1, NUTM2A-AS1, MALAT1, RP11-903H12.3, CASC17, AQP4-AS1, RP11-567M16.1, LL22NC03-86G7.1] |

*Other includes short_ncRNA, small_RNA, structural_RNA, and uncertain_coding.
### Table 4: Final list of noncoding RNAs that overlapped with NDDs or schizophrenia related GWAS/CNVs.

| variant type | ncRNA chr | ncRNA start position | ncRNA end position | ncRNA symbol | eQTL linked genes |
|--------------|-----------|----------------------|--------------------|--------------|-------------------|
| **NDDs**     |           |                      |                    |              |                   |
| CNV          | chr1      | 247094914            | 247098641          | CATG0000004219.0 | OR2W3            |
| GWAS         | chr4      | 4543868              | 4822163            | STX18-AS1    | EVC               |
| GWAS         | chr4      | 120987634            | 12133622           | RP11-679C8.2 | MAD2L1, C4orf3    |
| GWAS         | chr5      | 87970840             | 88063654           | CTC-467M3.1  | TEMEM161B         |
| GWAS         | chr11     | 71159674             | 71163869           | RP11-660L16.2| KRTAP5-7, KRTAP5-8, KRTAP5-10 |
| GWAS         | chr12     | 77717925             | 78222393           | RP1-34H18.1  | ZDHHC17           |
| GWAS         | chr17     | 68608010             | 69379611           | CASC17       | SOX9              |
| GWAS         | chr18     | 74696810             | 74700868           | CATG0000003662.7 | ZNF236          |
| GWAS         | chr19     | 6393588              | 6411788            | CTB-180A7.8  | SLC25A41, SLC25A23, ALKBH7, CLPP |
| **Schizophrenia** |           |                      |                    |              |                   |
| GWAS         | chr1      | 200638614            | 200663382          | RP11-92G12.3 | DDX59, KIF14      |
| GWAS         | chr2      | 6072923              | 6143655            | AC073479.1   | DKFZP761K2322(ensemble) |
| GWAS         | chr4      | 4543868              | 4822163            | STX18-AS1    | EVC               |
| GWAS         | chr4      | 86068874             | 86305742           | CATG0000006925.6 | CDS1           |
| GWAS         | chr5      | 87970840             | 88063654           | CTC-467M3.1  | TEMEM161B         |
| GWAS         | chr5      | 151304308            | 152109235          | CTB-1202.1   | GLRA1, G3BP1, NMUR2 |
| GWAS         | chr6      | 111803916            | 111924133          | TRAF3IP2-AS1 | KIAA1919, REV3L   |
| GWAS         | chr10     | 88963526             | 89102347           | NUTM2A-AS1   | NUTM2A, NUTM2D, FAM35A |
| GWAS         | chr11     | 65263865             | 65276602           | MALAT1       | AP000769.1        |
| GWAS         | chr14     | 21153505             | 21268108           | RP11-903H12.3| RNAE3, RNAE4, RNAE6 |
| GWAS         | chr17     | 68608010             | 69379611           | CASC17       | SOX9              |
| GWAS         | chr18     | 24235508             | 24771692           | AQP4-AS1     | KCTD1             |
| GWAS         | chr18     | 77363391             | 77360135           | RP11-567M16.1| CTDP1             |
| GWAS         | chr22     | 22292599             | 22300188           | LL22NC03-86G7.1 | TOP3B            |

*Look at Supplementary table S13 for more details.

**Figures legends**

**Figure 1. An overview of the integrative bioinformatics pipeline used in this study.** Out of 60,681 noncoding genes in the list, we have started with selection of the ones with significant expression for brain tissue, overlapping with ENCODE predicted chromatin states presented in brain defined as ‘enhancer’ or ‘promoter’, and containing brain related eQTL polymorphism(s) that interacts with at least one protein-coding
gene. Based on the above criteria, 908 noncoding RNAs annotated as putative enhancers in brain, focusing on to identify enhancer ncRNAs with possible regulatory function in neurodevelopmental disorders. We then explored the number of candidate ncRNA enhancers that contain NDD associated GWAS or overlap with NDD related CNVs whereas their eQTL genes do not contain GWAS/CNV. As a result, we identified 82 candidate ncRNA enhancers with potential regulatory function in neurodevelopmental disorders.

**Figure 2.** A) Distribution of noncoding genes available in the gene list of this study. Out of 84,065 genes available in the final list of the study, 60,681 are noncoding RNA genes. The figure shows fraction of each noncoding types through all 60,681 noncoding genes. The most fraction of ncRNAs are IncRNAs and pseudogenes while tRNAs, structural RNAs, and 3prime overlapping RNAs are the least ones. B) Pie chart derived from ChromHMM data overlapped with ncRNAs. Out of 60,681 noncoding genes, 9.45% overlapped with promoters, 4.85% overlapped with enhancers, and 14.31% overlapped with either promoters or enhancers. C) Pie chart derived from ChromHMM data overlapped with coding genes. Out of 22,698 coding genes, 29.24% overlapped with promoters, 4.82% overlapped with enhancers, and 34.06% overlapped with either promoters or enhancers.

**Figure 3.** Expression profile of 17,743 noncoding RNA genes. Noncoding RNA genes that encompass at least one nervous system related eQTL polymorphism contain proportionally more nervous system enriched genes than expected. Hierarchical clustering of the 17,743 noncoding RNA genes based on their expression profiles revealed a substantial proportion of these genes were highly expressed in the brain while smaller clusters of genes were highly expressed in blood and T-cells tissues.

**Figure 4.** Another example loci of noncoding gene *CTB-180A7.8* interacting with eQTL linked gene *ALKBH7*. *CTB-180A7.8* overlaps with HMM predicted strong enhancer, strong signals of chromatin states H3K27ac, H3K4me1, and H3K9ac, all presented in brain. This IncRNA also overlaps with multiple FANTOM5 enhancers and
contains one NDD related GWAS SNP. This IncRNA also significantly deleted in autistic individuals, while \textit{ALKBH7}, the eQTL linked gene, does not overlap with either GWAS SNPs or ASD related CNVs. All these observations may indicate a putative enhancer activity of this noncoding RNA.

**Figure 5.** An example loci of noncoding gene \textit{CATG00000053385} interacting with eQTL linked gene \textit{SLC13A3}. \textit{CATG00000053385} overlaps with HMM predicted strong enhancer, chromatin states H3K27ac, H3K4me1, and H3K9ac, all presented in brain. This IncRNA also overlaps with multiple FANTOM5 enhancers. All these observations may indicate a putative enhancer activity of this noncoding RNA. Interestingly, \textit{CATG00000053385} encompasses two NDD related GWAS SNPs, while \textit{SLC13A3}, the eQTL linked gene, does not overlap with either GWAS SNPs or ASD related CNVs. MHiC tool [72] has been used to generate the figure.

**Supplementary tables legends**

**Supplementary table S1:** Coding and noncoding RNAs that overlapped with histone mark and ChromHMM signals.

**Supplementary table S2:** Results of overlapping noncoding RNAs with brain-related eQTL polymorphism.

**Supplementary table S3:** Statistics related to the brain eQTL genes that interact with coding and noncoding genes.

**Supplementary table S4:** Statistics of minimum, maximum, and average distance of eQTL interactions for noncoding RNAs with at least one nervous systems related eQTL polymorphism.
Supplementary table S5: List of noncoding RNAs with at least one nervous systems related eQTL polymorphism.

Supplementary table S6: Distribution of brain eQTL polymorphisms on different types of noncoding genes.

Supplementary table S7: List of brain-enriched noncoding genes.

Supplementary table S8: List of noncoding RNAs as putative enhancers based on the criteria used in the study.

Supplementary table S9: List of putative enhancer ncRNAs that contains neurodevelopmental related GWAS SNP.

Supplementary table S10: Results of overlapping noncoding genes with at least one nervous system related eQTL polymorphism with neurodevelopmental related GWAS SNP.

Supplementary table S11: A full list of neurodevelopmental related CNVs identified by SNATCNV.

Supplementary table S12: A full list of schizophrenia related CNVs identified by SNATCNV.

Supplementary table S13: List of putative enhancer ncRNAs that overlap with neurodevelopmental- or schizophrenia-associated CNVs.

Supplementary table S14: Literature search for enhancer-ncRNAs.
Supplementary table S15: Decipher analysis.

Supplementary table S16: Literature search for 144 eQTL linked coding genes interacting with the 82 enhancer ncRNAs.

Supplementary table S17: Decipher analysis for enhancer-ncRNAs with at least three evidences in DECIPHER.

Supplementary table S18: The combined list of genes used in this study.

Supplementary table S19: Total number of entries for eQTL data of thirteen different tissues of brain.

Supplementary table S20: The combined list of GWAS used in this study.
significantly expressed in brain tissue
overlap with ChromHMM promoters or enhancers
overlap with at least one eQTL that interacts with at least one protein-coding gene

908 ncRNAs

60,681 ncRNAs

Applying Criteria

contain GWAS
contain CNV

eQTL genes do not contain GWAS
eQTL genes do not contain CNV
eQTL genes have no other interaction

Candidate ncRNAs overlapped with GWAS/CNV for 12 different ND phenotypes

Schizophrenia

12 different ND phenotypes

Candidate ncRNAs overlapped with GWAS/CNV for Schizophrenia

37 154

24 2

8 1

9 68

0 56

0 14
A

B

NON-CODING GENES

promoter 9%
enhancer 5%
other 86%

C

CODING GENES

promoter 29%
enhancer 5%
other 66%
Figure 3

- brain
- testis
- blood and T-cell
- male reproductive system

[Image of a heatmap with clusters labeled as mentioned above]
